Get the Stockscreener App
2.83
0.35%
0.01
Pre-market:
2.85
0.02
+0.71%
Esperion Therapeutics Inc stock is traded at $2.83, with a volume of 7.22M.
It is up +0.35% in the last 24 hours and up +2.91% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$2.82
Open:
$2.83
24h Volume:
7.22M
Relative Volume:
1.07
Market Cap:
$668.54M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-1.3349
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
-8.71%
1M Performance:
+2.91%
6M Performance:
+252.96%
1Y Performance:
+31.63%
1-Day Range:
$2.66
$2.91
1-Week Range:
$2.66
$3.2583
52-Week Range:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.83 | 668.54M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
118.14 | 52.35B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.07 | 44.67B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.61 | 43.10B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
VTRS
Viatris Inc
|
10.71 | 12.28B | 14.33B | -3.79B | 1.84B | -3.17 |
|
UTHR
United Therapeutics Corp
|
476.59 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Will Esperion Therapeutics Inc. stock outperform international peers2025 Earnings Impact & Weekly Market Pulse Updates - newser.com
Is Esperion Therapeutics Inc. stock a safe investment in uncertain marketsGold Moves & Expert Approved Trade Ideas - newser.com
Will earnings trigger a reversal in Esperion Therapeutics Inc.2025 Technical Overview & Smart Investment Allocation Insights - newser.com
Is Esperion Therapeutics Inc. stock undervalued vs historical averages2025 Price Action Summary & Intraday High Probability Setup Alerts - newser.com
Will Esperion Therapeutics Inc. stock recover faster than marketWeekly Investment Summary & AI Powered Trade Plan Recommendations - newser.com
Can Esperion Therapeutics Inc. stock double in next 5 years2025 Momentum Check & Stock Portfolio Risk Management - newser.com
Esperion’s cholesterol drug Nilemdo receives Health Canada approval By Investing.com - Investing.com Nigeria
Esperion partner announces HLS Therapeutics received approval of Nilemdo for the reduction of LDL cholesterol in Canadians at risk of cardiovascular disease - MarketScreener
HLS Therapeutics Receives Health Canada Approval to Market NILEMDO® for LDL-Cholesterol Reduction in Partnership with Esperion - Quiver Quantitative
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease - The Manila Times
Esperion (NASDAQ: ESPR) HLS secures Health Canada approval for NILEMDO launch Q2 2026 - Stock Titan
Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
[Form 3] Esperion Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Relative strength of Esperion Therapeutics Inc. in sector analysisInflation Watch & Breakout Confirmation Alerts - newser.com
Why retail investors favor Esperion Therapeutics Inc. stockRisk Management & Free Expert Verified Stock Movement Alerts - newser.com
Is Esperion Therapeutics Inc. stock reversal real or fake2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
Can volume confirm reversal in Esperion Therapeutics Inc.Swing Trade & Free Expert Verified Stock Movement Alerts - newser.com
Identifying reversal signals in Esperion Therapeutics Inc.July 2025 Macro Moves & Capital Protection Trading Alerts - newser.com
Multi asset correlation models including Esperion Therapeutics Inc.July 2025 Update & Safe Entry Zone Identification - newser.com
Why Esperion Therapeutics Inc. is moving todayPortfolio Profit Report & Real-Time Volume Trigger Notifications - newser.com
How to integrate Esperion Therapeutics Inc. into portfolio analysis toolsJuly 2025 Trends & Consistent Profit Trade Alerts - newser.com
Can Esperion Therapeutics Inc. stock deliver surprise earnings beatTrend Reversal & Free Reliable Trade Execution Plans - newser.com
Smart tools for monitoring Esperion Therapeutics Inc.’s price actionWeekly Profit Recap & Precise Swing Trade Entry Alerts - newser.com
Esperion Therapeutics Reports Strong Q3 Revenue Growth - MSN
ESPR | Esperion Therapeutics Inc. SEC Filings - MarketWatch
How Esperion Therapeutics Inc. stock benefits from global expansionWeekly Risk Report & Stock Market Timing Techniques - newser.com
Will Esperion Therapeutics Inc. (0ET) stock benefit from mergersAnalyst Upgrade & Reliable Intraday Trade Alerts - newser.com
Will Esperion Therapeutics Inc. stock gain from lower inflation2025 Dividend Review & Fast Momentum Stock Entry Tips - newser.com
What drives Esperion Therapeutics Inc stock priceEnergy Sector Updates & Free Discover Fast Growing Stocks - earlytimes.in
Citizens reiterates Market Outperform rating on Esperion stock at $4 By Investing.com - Investing.com Nigeria
Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
3.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):